Format

Send to

Choose Destination
Cancer Discov. 2018 Nov;8(11):1491. doi: 10.1158/2159-8290.CD-18-1115.

Correction: Phase I Dose-Escalation Study of Taselisib, an Oral PI3KInhibitor, in Patients with Advanced Solid Tumors.

[No authors listed]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center